LTR Pharma Limited (ASX:LTP)

Market Cap	83.62M -24.9%
Revenue (ttm)	1.13M +126.4%
Net Income	-8.95M
EPS	-0.05
Shares Out	181.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,776
Average Volume	188,634
Open	0.4500
Previous Close	0.4350
Day's Range	0.4500 - 0.4600
52-Week Range	0.2700 - 0.8100
Beta	3.89
RSI	41.54
Earnings Date	Feb 26, 2026

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LTP

Financial Performance

In fiscal year 2025, LTR Pharma's revenue was 1.51 million, an increase of 2978.25% compared to the previous year's 49,002. Losses were -5.59 million, -19.57% less than in 2024.